Table 2 Unadjusted and adjusted Cox model estimates for association of post-CARTx, pre-vaccine covariates with seroresponse

From: Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response

Baseline variablea

Unadjusted HR (95% CI)

p value

Multivariate model 1b adjusted HR (95% CI)

p value

Multivariate model 2c adjusted HR (95% CI)

p value

CARTx target

      

 CD19/20

1.0 (Reference)

 

1.0 (Reference)

 

1.0 (Reference)

 

 BCMA

2.82 (1.05, 7.58)

0.04

2.53 (1.05, 6.08)

0.04

2.46 (0.87, 6.95)

0.09

Time from CARTx to first vaccine dose

      

 per 1 month increase

1.01 (0.97, 1.04)

0.80

    

CD19+ B cell count

      

 per log10 increase

2.18 (1.47, 3.23)

<0.001

2.16 (1.44, 3.23)

<0.001

  

 <20 cells/µL

1.0 (Reference)

-

  

1.0 (Reference)

 

 ≥20 cells/µL

3.54 (1.62, 7.75)

0.002

  

3.72 (1.72, 8.01)

<0.001

  1. aHR indicates hazard ratio; CI, confidence interval. Estimates averaged across pathogens: Hepatitis A (n = 22 participants), Hepatitis B (n = 39), Haemophilus influenzae type B (n = 42), C. diphtheriae (n = 13), S. pneumoniae (n = 44). P values correspond to two-sided testing (matching confidence intervals) and are exact when ≥0.001. No adjustments were made for multiple comparisons.
  2. bEstimates adjusted for CARTx target and continuous log10 CD19+ B cell count.
  3. cEstimates adjusted for CARTx target and binary CD19+ B cell count.
Back to article page